Author: Gary Anderson
-
A Consortium Including Arctic Therapeutics Launches Synaptiq with Acquisition of Clinical-Stage SYN-001 Program
AKUREYRI, ICELAND AND PHILADELPHIA, PA – JULY 23, 2026 – A consortium of European and US-based investors and Nobias Therapeutics today announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage biotechnology company dedicated to advancing SYN-001 for the treatment of neuropsychiatric symptoms associated with 22q11DS. With the acquisition of Nobias Therapeutics’ lead asset, NB-001 (now…
-
Fujirebio’s FDA-approved Alzheimer’s blood test hailed as ‘game changer’
The first blood test for Alzheimer’s has been approved in the USA, paving the way for earlier diagnosis and preventive treatment of the disease, FierceBiotech reported. The FDA has now green-lit the Lumipulse G test, developed by Fujirebio Diagnostics, for patients aged 55 and over who exhibit signs or symptoms of Alzheimer’s. Used alongside clinical…